Adnan Malik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Adnan Malik has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Muhammad Imran Malik
Airedale General Hospital, West Yorkshire, England
12 shared publicationsShahbaz Qureshi
Mountain Vista Medical Center, Mesa, USA
7 shared publicationsSadia Javaid
Nishtar Hospital Multan, Multan, Pakistan
6 shared publicationsKhadija Naseem
West Virginia Charleston Med Ctr, Charleston, WV USA
4 shared publicationsMahum Nadeem
Oklahoma Univ, Med Ctr, Oklahoma City, OK USA
4 shared publications- Shailendra Singh
Division of Gastroenterology and Hepatology, Department of Medicine, West Virginia University, Morgantown, USA
4 shared publications
Latest Publications
- 14 October 2024
- Published by Springer Nature in International Journal of Obesity
- Vol. 49  (1) , 54-62
Comparative effectiveness of metabolic and bariatric surgeries: a network meta-analysis
Bariatric surgery is recommended for patients with unhealthy weight. Our study aim to compare and rank different bariatric surgical approaches in reducing weight parameters. We searched MEDLINE, Cochrane CENTRAL, Scopus, and Web of Science databases from inception to September 2023. We extracted all outcomes as mean change from the baseline. The mean difference and 95% confidence interval were used as a summary measure. All analysis was conducted with R version 4.2.2 (2022-10-31) and R Studio version 2022.07.2 (2009–2022) (RStudio, Inc.). Included surgeries were: Biliopancreatic diversion (BPD-RYGB), Roux-en-Y Gastric Bypass (RYGB), Laparoscopic Gastric Plication (LGP), Duodenal-Jejunal Bypass Sleeve (DJBS), Single-anastomosis gastric bypass (SAGB), Laparoscopic vertical banded gastroplasty (LVBG), Sleeve Gastrectomy (SG), Laparoscopic adjustable gastric banding (LAGB), Gastric plication, Biliopancreatic diversion (BPD), and Intra-gastric balloon (IGB). Only clinical trials were included, with outcomes focused on weight parameters such as reductions in BMI (kg/m²), weight (kg), waist circumference (cm), fat mass (kg), and excess weight loss (EWL) (%). Our analysis of 67 studies showed that SADI-S was the best surgical technique in decreasing BMI (kg/m2) (MD = −18.06; 95% CI [−25.31; −10.81]) and DS follows in efficacy with a P-score (MD = −18.88; 95% CI [−31.15; −6.62]) however the pooled analysis was heterogeneous (I2 = 98.5%). For weight (kg), waist circumference (cm), and fat mass (kg), BPD-RYGB was the best surgical technique to reduce these parameters (MD = −41.48; 95% CI [−47.80, −35.51], MD = −29.08; 95% CI [−37.16, −21.00], and MD = −31.11; 95% CI [−38.77, −23.46]; respectively). The pooled analysis was heterogeneous except in fat mass (I2 = 0%, p-value = 0.8). Our network meta-analysis showed that the best surgical technique in increasing EWL (%) was RY-DS (MD = −61.27; % CI [−91.72; −30.82]) the next one in efficacy according to P-score was LVBG (MD = −59.03; % CI [−84.47; −33.59]). SADI-S is most effective in reducing BMI followed by RYGB. DS was associated with most estimated weight loss %.
- 14 October 2024
- Published by Springer Nature in International Journal of Obesity
- Vol. 49  (1) , 54-62
Comparative effectiveness of metabolic and bariatric surgeries: a network meta-analysis
Bariatric surgery is recommended for patients with unhealthy weight. Our study aim to compare and rank different bariatric surgical approaches in reducing weight parameters. We searched MEDLINE, Cochrane CENTRAL, Scopus, and Web of Science databases from inception to September 2023. We extracted all outcomes as mean change from the baseline. The mean difference and 95% confidence interval were used as a summary measure. All analysis was conducted with R version 4.2.2 (2022-10-31) and R Studio version 2022.07.2 (2009–2022) (RStudio, Inc.). Included surgeries were: Biliopancreatic diversion (BPD-RYGB), Roux-en-Y Gastric Bypass (RYGB), Laparoscopic Gastric Plication (LGP), Duodenal-Jejunal Bypass Sleeve (DJBS), Single-anastomosis gastric bypass (SAGB), Laparoscopic vertical banded gastroplasty (LVBG), Sleeve Gastrectomy (SG), Laparoscopic adjustable gastric banding (LAGB), Gastric plication, Biliopancreatic diversion (BPD), and Intra-gastric balloon (IGB). Only clinical trials were included, with outcomes focused on weight parameters such as reductions in BMI (kg/m²), weight (kg), waist circumference (cm), fat mass (kg), and excess weight loss (EWL) (%). Our analysis of 67 studies showed that SADI-S was the best surgical technique in decreasing BMI (kg/m2) (MD = −18.06; 95% CI [−25.31; −10.81]) and DS follows in efficacy with a P-score (MD = −18.88; 95% CI [−31.15; −6.62]) however the pooled analysis was heterogeneous (I2 = 98.5%). For weight (kg), waist circumference (cm), and fat mass (kg), BPD-RYGB was the best surgical technique to reduce these parameters (MD = −41.48; 95% CI [−47.80, −35.51], MD = −29.08; 95% CI [−37.16, −21.00], and MD = −31.11; 95% CI [−38.77, −23.46]; respectively). The pooled analysis was heterogeneous except in fat mass (I2 = 0%, p-value = 0.8). Our network meta-analysis showed that the best surgical technique in increasing EWL (%) was RY-DS (MD = −61.27; % CI [−91.72; −30.82]) the next one in efficacy according to P-score was LVBG (MD = −59.03; % CI [−84.47; −33.59]). SADI-S is most effective in reducing BMI followed by RYGB. DS was associated with most estimated weight loss %.
- Open Access
- 29 August 2024
- Published by Elsevier in Annals of Hepatology
- Vol. 29  (6) , 101544
Relationship between sarcopenia and metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis
- 29 August 2024
- Published by Elsevier in Annals of Hepatology
- Vol. 29  (6) , 101544
Open AccessRelationship between sarcopenia and metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis
- 13 August 2024
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 31  (5) , e560-e564
The Efficacy and Safety of Propofol Versus Etomidate for Endoscopic Retrograde Cholangiopancreatography: A Systematic Review and Meta-Analysis
- 13 August 2024
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 31  (5) , e560-e564
The Efficacy and Safety of Propofol Versus Etomidate for Endoscopic Retrograde Cholangiopancreatography: A Systematic Review and Meta-Analysis
- Open Access
- 25 July 2024
- Published by SAGE Publications in Science Progress
- Vol. 107  (3)
Histopathological features of idiopathic portal hypertension: A systematic review and meta-analysis
Background: Portal hypertension (PH) is a clinically significant entity that could present with life-threatening gastrointestinal bleeding. Cirrhosis is the most common cause of PH, with well-documented histopathology and etiology. However, in idiopathic portal hypertension (IPH), no single histopathologic finding is associated with PH. Our systematic review aims to identify and summarize the prevalence of the common histological findings of IPH. Methods: We systematically searched PubMed, Cochrane CENTRAL, Web of Science, and Scopus till 1ST March 2022 for studies describing the histopathological features of IPH. Data were extracted from eligible studies and pooled as events rate and 95% confidence interval (CI) using binary random-effects model by open meta-analyst software. Results: We included 23 retrospective studies with a total sample size of 813 patients. The overall incidence of nodular regenerative hyperplasia was 38.6%, 59.8% for portal fibrosis, 51.3% for periportal fibrosis, 39.3% for perisinusoidal fibrosis, 89.8% for portal vein sclerosis, 42.2% for portal inflammation, 53.3% for mega-sinusoids, 39.5% for thickening of portal vein branches, 93.8% for narrowing of portal veins, 53.3% for hepatic veins/venous outflow obstruction, 51.4% for aberrant portal/periportal vessels, 42.4% for shunt vessel, 50.9% for ductular proliferation, and 16.3% for steatosis. Conclusion: Due to the relatively non-pathognomonic and non-specific nature of IPH, a combination of different histological features such as the portal and periportal fibrosis, portal vein sclerosis, mega-sinusoids, narrowing of portal veins, hepatic venous outflow obstruction, aberrant portal or periportal vessels, and ductular proliferation may be of value in diagnosing IPH as the incidence rate of these features was at approximately 50%.
- 25 July 2024
- Published by SAGE Publications in Science Progress
- Vol. 107  (3)
Open AccessHistopathological features of idiopathic portal hypertension: A systematic review and meta-analysis
Background: Portal hypertension (PH) is a clinically significant entity that could present with life-threatening gastrointestinal bleeding. Cirrhosis is the most common cause of PH, with well-documented histopathology and etiology. However, in idiopathic portal hypertension (IPH), no single histopathologic finding is associated with PH. Our systematic review aims to identify and summarize the prevalence of the common histological findings of IPH. Methods: We systematically searched PubMed, Cochrane CENTRAL, Web of Science, and Scopus till 1ST March 2022 for studies describing the histopathological features of IPH. Data were extracted from eligible studies and pooled as events rate and 95% confidence interval (CI) using binary random-effects model by open meta-analyst software. Results: We included 23 retrospective studies with a total sample size of 813 patients. The overall incidence of nodular regenerative hyperplasia was 38.6%, 59.8% for portal fibrosis, 51.3% for periportal fibrosis, 39.3% for perisinusoidal fibrosis, 89.8% for portal vein sclerosis, 42.2% for portal inflammation, 53.3% for mega-sinusoids, 39.5% for thickening of portal vein branches, 93.8% for narrowing of portal veins, 53.3% for hepatic veins/venous outflow obstruction, 51.4% for aberrant portal/periportal vessels, 42.4% for shunt vessel, 50.9% for ductular proliferation, and 16.3% for steatosis. Conclusion: Due to the relatively non-pathognomonic and non-specific nature of IPH, a combination of different histological features such as the portal and periportal fibrosis, portal vein sclerosis, mega-sinusoids, narrowing of portal veins, hepatic venous outflow obstruction, aberrant portal or periportal vessels, and ductular proliferation may be of value in diagnosing IPH as the incidence rate of these features was at approximately 50%.
- Open Access
- 1 June 2024
- Published by Elmer Press, Inc. in Gastroenterology Research
- Vol. 17  (3) , 133-145
The Risk of Infection-Caused Mortality in Gastric Adenocarcinoma: A Population-Based Study
The Risk of Infection-Caused Mortality in Gastric Adenocarcinoma: A Population-Based Study
- 1 June 2024
- Published by Elmer Press, Inc. in Gastroenterology Research
- Vol. 17  (3) , 133-145
Open AccessThe Risk of Infection-Caused Mortality in Gastric Adenocarcinoma: A Population-Based Study
The Risk of Infection-Caused Mortality in Gastric Adenocarcinoma: A Population-Based Study
- 8 May 2024
- Published by University of Toronto Press Inc. (UTPress) in Canadian Liver Journal
- Vol. 7  (2) , 299-315
Effects of curcumin in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis
Background: Curcumin is an anti-inflammatory that is proposed to have a positive impact on patients with non-alcoholic fatty liver disease (NAFLD). We aim to assess the effects of curcumin in patients with NAFLD. Methods: Clinical trials from PubMed, Scopus, the Web of Science, and Cochrane CENTRAL with variables alanine transferase, aspartate transaminase, alkaline phosphatase, glycated hemoglobin (HBA1c), BMI, waist circumference, total cholesterol, total glycerides, high-density lipoproteins, and low-density lipoproteins were included. Homogeneous and heterogeneous were analyzed under a fixed-effects model and the random-effects model, respectively. Results: Fourteen clinical trials found that curcumin has no statistically significant effect on alanine transferase (MD = −2.20 [−6.03, 1.63], p = 0.26], aspartate transaminase (MD = 1.37 [−4.56, 1.81], p = 0.4), alkaline phosphatase (MD = 3.06 [−15.85, 9.73], p = 0.64), glycated hemoglobin (HBA1c), (MD = −0.06 [−0.13, 0.02], p = 0.16], and BMI (MD = 0.04 [−0.38, 0.46], p = 0.86). Curcumin reduced the waist circumference (MD = −4.87 [−8.50, −1.25], p = 0.008). Lipid profile parameters were not significant, except the total glycerides (MD = −13.22 [−24.19, −2.24], p = 0.02). Conclusions: Curcumin significantly reduces total glycerides and waist circumference in NAFLD.
- 8 May 2024
- Published by University of Toronto Press Inc. (UTPress) in Canadian Liver Journal
- Vol. 7  (2) , 299-315
Effects of curcumin in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis
Background: Curcumin is an anti-inflammatory that is proposed to have a positive impact on patients with non-alcoholic fatty liver disease (NAFLD). We aim to assess the effects of curcumin in patients with NAFLD. Methods: Clinical trials from PubMed, Scopus, the Web of Science, and Cochrane CENTRAL with variables alanine transferase, aspartate transaminase, alkaline phosphatase, glycated hemoglobin (HBA1c), BMI, waist circumference, total cholesterol, total glycerides, high-density lipoproteins, and low-density lipoproteins were included. Homogeneous and heterogeneous were analyzed under a fixed-effects model and the random-effects model, respectively. Results: Fourteen clinical trials found that curcumin has no statistically significant effect on alanine transferase (MD = −2.20 [−6.03, 1.63], p = 0.26], aspartate transaminase (MD = 1.37 [−4.56, 1.81], p = 0.4), alkaline phosphatase (MD = 3.06 [−15.85, 9.73], p = 0.64), glycated hemoglobin (HBA1c), (MD = −0.06 [−0.13, 0.02], p = 0.16], and BMI (MD = 0.04 [−0.38, 0.46], p = 0.86). Curcumin reduced the waist circumference (MD = −4.87 [−8.50, −1.25], p = 0.008). Lipid profile parameters were not significant, except the total glycerides (MD = −13.22 [−24.19, −2.24], p = 0.02). Conclusions: Curcumin significantly reduces total glycerides and waist circumference in NAFLD.
- Open Access
- 30 March 2024
- Published by Romanian Society of Gastroenterology and Hepatology in Journal of Gastrointestinal and Liver Diseases
- Vol. 33  (1) , 137-138
Prone position vs. left lateral decubitus position in endoscopic retrograde cholangiopancreatography: a meta-analysis
- 30 March 2024
- Published by Romanian Society of Gastroenterology and Hepatology in Journal of Gastrointestinal and Liver Diseases
- Vol. 33  (1) , 137-138
Open AccessProne position vs. left lateral decubitus position in endoscopic retrograde cholangiopancreatography: a meta-analysis
- Open Access
- 7 March 2024
- Published by Elsevier in Annals of Hepatology
- Vol. 29  (4) , 101495
Efficacy and safety of terlipressin and albumin vs. noradrenaline and albumin in adult patients with hepatorenal syndrome: A systematic review and meta-analysis
- 7 March 2024
- Published by Elsevier in Annals of Hepatology
- Vol. 29  (4) , 101495
Open AccessEfficacy and safety of terlipressin and albumin vs. noradrenaline and albumin in adult patients with hepatorenal syndrome: A systematic review and meta-analysis
- 26 February 2024
- Published by University of Toronto Press Inc. (UTPress) in Canadian Liver Journal
- Vol. 7  (1) , 40-53
Effects of silymarin use on liver enzymes and metabolic factors in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis
Background: Fatty liver disease comprises a wide range of related liver disorders affecting mainly people who drink no or minimal amounts of alcohol. Silymarin is a member of the Carduus marianum family that has been used for centuries to treat different diseases. There is little evidence supporting its efficacy in humans. Objectives: To evaluate the effects of Silymarin in patients with non alcoholic fatty liver disease (NAFLD) or recently renamed metabolic dysfunction-associated steatotic liver disease (MASLD). Methods: We searched PubMed, SCOPUS, Web of Science, and Cochrane Library for relevant clinical trials assessing the use of silymarin in patients with NAFLD. A risk of bias assessment was performed using Cochrane's risk of bias tool. We included the following outcomes: alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyl transferase (GGT), total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL) (mg/dL), degree of fibrosis resolution, low-density lipoprotein (LDL), and HOMA-IR. We analyzed continuous data using mean difference (MD) and relative 95% confidence interval (CI). Results: We included nine clinical trials. We found that silymarin significantly reduced the levels of ALT (MD= -17.12 [-28.81, -4.43]), (P < 0.004), AST (MD= -12.56 [-19.02, -6.10]), (P < 0.0001) and TG (MD = −22.60 [−23.83, −21.38]) ( p < 0.00001). It also improved HDL (MD= 2.13 [1.60, 2.66]), (P < 0.01)). There was no significant difference regarding GGT (P=o.07), TC (P= 0.52), LDL (P= 0.06), HOMA-IR (P= 0.06) and BMI (p=0.1).One study reported significant improvement in the degree of fibrosis (P = 0.023). Conclusion: Silymarin treatment significantly reduces biochemical and transaminase levels in patients with MASLD.
- 26 February 2024
- Published by University of Toronto Press Inc. (UTPress) in Canadian Liver Journal
- Vol. 7  (1) , 40-53
Effects of silymarin use on liver enzymes and metabolic factors in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis
Background: Fatty liver disease comprises a wide range of related liver disorders affecting mainly people who drink no or minimal amounts of alcohol. Silymarin is a member of the Carduus marianum family that has been used for centuries to treat different diseases. There is little evidence supporting its efficacy in humans. Objectives: To evaluate the effects of Silymarin in patients with non alcoholic fatty liver disease (NAFLD) or recently renamed metabolic dysfunction-associated steatotic liver disease (MASLD). Methods: We searched PubMed, SCOPUS, Web of Science, and Cochrane Library for relevant clinical trials assessing the use of silymarin in patients with NAFLD. A risk of bias assessment was performed using Cochrane's risk of bias tool. We included the following outcomes: alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyl transferase (GGT), total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL) (mg/dL), degree of fibrosis resolution, low-density lipoprotein (LDL), and HOMA-IR. We analyzed continuous data using mean difference (MD) and relative 95% confidence interval (CI). Results: We included nine clinical trials. We found that silymarin significantly reduced the levels of ALT (MD= -17.12 [-28.81, -4.43]), (P < 0.004), AST (MD= -12.56 [-19.02, -6.10]), (P < 0.0001) and TG (MD = −22.60 [−23.83, −21.38]) ( p < 0.00001). It also improved HDL (MD= 2.13 [1.60, 2.66]), (P < 0.01)). There was no significant difference regarding GGT (P=o.07), TC (P= 0.52), LDL (P= 0.06), HOMA-IR (P= 0.06) and BMI (p=0.1).One study reported significant improvement in the degree of fibrosis (P = 0.023). Conclusion: Silymarin treatment significantly reduces biochemical and transaminase levels in patients with MASLD.
- Open Access
- 1 August 2023
- Published by Elmer Press, Inc. in Gastroenterology Research
- Vol. 16  (4) , 209-216
Fecal Microbiota Transplantation in Human Immunodeficiency Virus-Infected Patient Population: A Systematic Review and Meta-Analysis
Fecal Microbiota Transplantation in Human Immunodeficiency Virus-Infected Patient Population: A Systematic Review and Meta-Analysis
- 1 August 2023
- Published by Elmer Press, Inc. in Gastroenterology Research
- Vol. 16  (4) , 209-216
Open AccessFecal Microbiota Transplantation in Human Immunodeficiency Virus-Infected Patient Population: A Systematic Review and Meta-Analysis
Fecal Microbiota Transplantation in Human Immunodeficiency Virus-Infected Patient Population: A Systematic Review and Meta-Analysis